NeoStem is developing therapies to address ischemia through our Ischemic Repair Program. Ischemia occurs when the supply of oxygenated blood in the body is restricted. Our therapeutics seek to reverse this restriction through the development and formation of new blood vessels.
NBS10 is being developed to treat damaged heart muscle following an acute myocardial infarction (“AMI” or heart attack). In November 2014, the Company announced its 6-month interim analysis for its PreSERVE AMI study, a randomized, double-blinded, placebo-controlled Phase 2 clinical trial testing NBS10.
If approved by Food and Drug Administration and/or other worldwide regulatory agencies and following successful completion of further trials, NBS10 would address a significant medical need for which there is currently no effective treatment, potentially improving longevity and quality of life for those suffering a STEMI (ST segment elevation myocardial infarction, a certain type of heart attack), and positioning the Company to capture a meaningful share of this worldwide market. Furthermore, the Ischemic Repair program has potential application across several cardiovascular indications, including chronic heart failure and critical limb ischemia.